Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study we analysed the cytogenetic findings of seven patients with CD56-positive putative NK cell lymphoma/leukaemia.
|
9326190 |
1997 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas.
|
8608237 |
1996 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To describe the clinical, pathological and molecular features in six cases of CD56+ lymphoma with cutaneous presentation.
|
12653743 |
2003 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD16/CD56 expression without CD38<sup>higher</sup> and the lack of CD16/CD56 with CD38<sup>higher</sup> expression proves to be a reliable, fast, and cost-effective method for diagnosing 11q aberration and MYC rearrangements in CD10(+) aggressive lymphomas, respectively.
|
29327714 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The diagnosis of NK cell lymphoma was made on the basis of morphological and immunological characteristics (CD3-CD56+) found on skin biopsy of one of multiple skin nodules which subsequently developed in association with splenomegaly, thrombocytopenia and continuing neutropenia.
|
9869207 |
1998 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia.
|
10800166 |
2000 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In type II EATL, lymphoma cells of the 16 (80%) and 11 (55%) cases were positive for CD56 and CD8, respectively.
|
21323966 |
2011 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Four patients with cutaneous CD4+ and CD56+ lymphoma were studied.
|
10828627 |
2000 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Five CD3- CD56+ lymphoma patients presenting with nodular lesions were identified among 180 immunophenotyped cutaneous lymphomas.
|
9470917 |
1997 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We report 4 cases of lymphomas/leukemias with the unusual CD56/CD4 phenotype.
|
11488062 |
2001 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CD4+/CD56+ hematodermic neoplasm (HN), formerly known as a blastic natural killer (NK) cell lymphoma, is a rare subtype of a cutaneous dendritic cell neoplasm notable for highly aggressive behavior.
|
18005171 |
2008 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, there seems to be a useful distinction between the classical NK/T type of nasal lymphoma (CD56+/n-cdk6+/CD44-/TcR-GR-) and PTL (CD56-/n-cdk6-/CD44+/TcR-GR+) involving the nasal region.
|
10879740 |
2000 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD2+, CD3-, CD56/NCAM+ malignant lymphoma with TCR beta gene rearrangement: a case report.
|
7485082 |
1995 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We consider that blastoid NK cell lymphoma is an extremely aggressive subtype of CD56-positive lymphomas, and high-dose chemotherapy with peripheral blood stem cell rescue should be included for the choice of the treatment.
|
10048432 |
1999 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Among these six cases, four female CD56(-)/CD44(-)/CD8(-)/CD45RO(+)/CD45RA(-) cases constituted a distinct group with a better prognosis than the rest of the male cases of sinonasal lymphomas.
|
12533686 |
2003 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We report the clinical and laboratory findings of a patient with an aggressive Epstein-Barr virus positive CD2+/CD56+ natural killer-cell lymphoma with a high mitotic activity and complex chromosomal abnormalities presenting with life-threatening pericardial and pleural effusions, disseminated skin lesions, breast nodule and large suprarenal masses.
|
11911423 |
2002 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this work was to study the expression of human leukocyte antigen G (HLA-G) and interleukin 10 (IL-10) in conjunction with expression of HLA-G killer-cell inhibitory receptor ligand immunoglobulin-like transcript 2 (ILT2) in CD3+, CD19+, CD56+ lymphomas, and ILT4 in CD14+ cells from patients with systemic lupus erythematosus (SLE).
|
22562117 |
2013 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of CD56 is associated with a poor prognosis in subcutaneous panniculitis-like T-cell lymphoma and blastic natural killer cell lymphoma.
|
17052504 |
2006 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, EBV may play an etiologic role in these CD56-positive lymphomas.
|
7520016 |
1994 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
NCAM (CD56)-positive malignant lymphoma.
|
7512851 |
1993 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Phenotypic and genotypic studies revealed that the lymphoma is originated from either NK- or γδ T-cell, both of which express CD56.
|
31041299 |
2019 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Described for the first time in 1994 as CD4+ cutaneous lymphoma with high expression of CD56, BPDCN has been known previously with various names such as blastic natural killer (NK) leukemia/lymphoma, agranular CD4+ CD56+ hematodermic neoplasm, and agranular CD4+ NK cell leukemia.
|
29237977 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Agranular CD4+CD56+ blastic natural killer leukemia/lymphoma.
|
11401089 |
2001 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This case demonstrated nasal cavity and cutaneous tumor infiltrates consistent with previously described CD3-negative, CD56-positive NK-cell lymphoma of the upper aerodigestive tract.
|
7530849 |
1994 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of the neural cell adhesion molecule (NCAM) (CD56, NKH-1) is a rare phenomenon in malignant lymphoma.
|
7532919 |
1995 |